Orexo’s Upcoming Presentations at Events during Second Half 2015

Uppsala, Sweden – August 25, 2015 – Orexo AB (publ) informs today that the
company will be presenting at the following events during the fall of 2015.

August 28:            Pareto Securities’ 6th Annual Health Care Seminar,
Stockholm

September 3:        Redeye Open Investor Forum, Stockholm

October 22:           Release of Orexo Q3 Interim Report followed by audio cast

October 30:           ProHearings Investor Presentation, Stockholm

November 18/19:  Jefferies Autumn 2015 Global Healthcare Conference, London

December 15:       Guggenheim’s Boston One-on-One Healthcare Day, Boston

Please visit the pages “Upcoming events” and “Investors” at www.orexo.com for
details and further updated information. In case of any additional upcoming
events not mentioned above, these will be announced on our corporate web site.

For further information, please contact
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

About Orexo
Orexo is a specialty pharmaceutical company commercializing its proprietary
product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an
advanced formulation of buprenorphine and naloxone using Orexo’s unique
knowledge and expertise in sublingual drug delivery. R&D is focusing on
reformulation of known substances to new improved products that meet great unmet
medical needs by using its patented proprietary technologies. Orexo’s share is
listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs
on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in
Uppsala, Sweden. www.orexo.com.

For information about ZUBSOLV and opioid dependence, please visit
www.zubsolv.com and www.outthemonster.com